Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agenus (AGEN) -- Ignore unavailable to you. Want to Upgrade?

To: Kirk © who wrote (142)	5/8/2024 12:43:23 AM
From: Area51	Read Replies (2) \| Respond to of 146

True. I think not a great deal for AGEN. One take I saw was that AGEN sold $400 million in future cash flows for $75 million. For a company with a marketcap of 250 million that is a pretty significant hit. And still they don't have near enough money to get them to cash flow breakeven right? Disappointing that that was the best they could do for raising some capital. Wainright analyst maintained a $40 price target after the deal, but Wainright is not that reliable in their price targets in my experience.